Strumento inattivo

Altre lingue Repro-Med Systems, Inc. OTC Bulletin Board

Azioni

US7599101026

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic	14/05
KORU Medical Systems Signs Supply Agreement for a Phase III Clinical Trial for a Novel Endocrinological Biologic	14/05
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Posts Q1 Revenue $8.2M, vs. Street Est of $7.5M	01/05
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth	01/05
KORU Medical Systems, Inc. reaffirms Financial Guidance for the Full Year of 2024	01/05
KORU Medical Systems, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024	17/04
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review	11/04
KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference	18/03
KORU Medical Systems, Inc. Enters into Loan and Security Agreement with HSBC Ventures USA Inc	13/03
KORU Medical Systems, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03
KORU Medical Systems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Earnings Flash (KRMD) KORU MEDICAL SYSTEMS Reports Q4 Revenue $7.2M, vs. Street Est of $6.9M	13/03
KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance	13/03
KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year 2024	13/03
KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic	11/03
KORU Medical Systems, Inc. Announces A Feasibility Study to Enter Ambulatory Infusion Settings with A Commercialized Biologic	11/03
KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin	06/03
KORU Medical Systems, Inc. Signs Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for Novel Subcutaneous Immunoglobulin	06/03
KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024	21/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Repro-Med Systems, Inc. OTC Bulletin Board

Azioni

US7599101026

Altre lingue

Filtri